Subscribe
istock-540832896_rs-photo-1
rs-photo / iStockphoto.com
21 November 2017Americas

Eli Lilly considers BMS trademark opposition

Eli Lilly appears to be mulling whether to oppose a trademark registered by Bristol-Myers Squibb (BMS) at the US Patent and Trademark Office.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Eli Lilly refused injunction against Teva, Actavis and Mylan
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Big Pharma
Eli Lilly defeated as Cialis patent found obvious on appeal
1 November 2017   The English Court of Appeal has ruled that patent claims protecting blockbuster drug Cialis (tadalafil) are invalid as obvious, handing victory to Actavis, Teva and Mylan.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Eli Lilly refused injunction against Teva, Actavis and Mylan
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Big Pharma
Eli Lilly defeated as Cialis patent found obvious on appeal
1 November 2017   The English Court of Appeal has ruled that patent claims protecting blockbuster drug Cialis (tadalafil) are invalid as obvious, handing victory to Actavis, Teva and Mylan.

More on this story

Big Pharma
Eli Lilly refused injunction against Teva, Actavis and Mylan
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Big Pharma
Eli Lilly defeated as Cialis patent found obvious on appeal
1 November 2017   The English Court of Appeal has ruled that patent claims protecting blockbuster drug Cialis (tadalafil) are invalid as obvious, handing victory to Actavis, Teva and Mylan.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages